GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Shiller PE Ratio

Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Shiller PE Ratio

: 32.85 (As of Today)
View and export this data going back to 1991. Start your Free Trial

As of today (2024-04-23), Regeneron Pharmaceuticals's current share price is $900.16. Regeneron Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $27.40. Regeneron Pharmaceuticals's Shiller PE Ratio for today is 32.85.

The historical rank and industry rank for Regeneron Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

REGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 26.26   Med: 68.29   Max: 4276.4
Current: 32.86

During the past years, Regeneron Pharmaceuticals's highest Shiller PE Ratio was 4276.40. The lowest was 26.26. And the median was 68.29.

REGN's Shiller PE Ratio is ranked worse than
51.75% of 143 companies
in the Biotechnology industry
Industry Median: 32.57 vs REGN: 32.86

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $10.190. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $27.40 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Regeneron Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.39 44.17 32.61 30.55 32.06

Regeneron Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.55 33.38 28.03 30.96 32.06

Competitive Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Shiller PE Ratio falls into.



Regeneron Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regeneron Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=900.16/27.4
=32.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=10.19/129.4194*129.4194
=10.190

Current CPI (Dec. 2023) = 129.4194.

Regeneron Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.610 99.695 0.792
201406 0.850 100.560 1.094
201409 0.730 100.428 0.941
201412 0.960 99.070 1.254
201503 0.660 99.621 0.857
201506 1.690 100.684 2.172
201509 1.820 100.392 2.346
201512 1.340 99.792 1.738
201603 1.590 100.470 2.048
201606 1.690 101.688 2.151
201609 2.270 101.861 2.884
201612 2.190 101.863 2.782
201703 2.160 102.862 2.718
201706 3.340 103.349 4.183
201709 3.320 104.136 4.126
201712 1.500 104.011 1.866
201803 4.160 105.290 5.113
201806 4.820 106.317 5.867
201809 5.170 106.507 6.282
201812 7.150 105.998 8.730
201903 3.990 107.251 4.815
201906 1.680 108.070 2.012
201909 5.860 108.329 7.001
201912 6.930 108.420 8.272
202003 5.430 108.902 6.453
202006 7.610 108.767 9.055
202009 7.390 109.815 8.709
202012 10.240 109.897 12.059
202103 10.090 111.754 11.685
202106 27.970 114.631 31.578
202109 14.330 115.734 16.024
202112 19.690 117.630 21.664
202203 8.610 121.301 9.186
202206 7.470 125.017 7.733
202209 11.660 125.227 12.050
202212 10.500 125.222 10.852
202303 7.170 127.348 7.287
202306 8.500 128.729 8.546
202309 8.890 129.860 8.860
202312 10.190 129.419 10.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (NAS:REGN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regeneron Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Executives
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Arthur F Ryan director CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
George Yancopoulos director, officer: President and CSO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Huda Y Zoghbi director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Marion Mccourt officer: SVP Commercial C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael S Brown director
Christopher R. Fenimore officer: VP, Controller REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Andrew J Murphy officer: EVP Research REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Kathryn Guarini director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Van Plew Daniel P officer: EVP & General Mgr Industrial O REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Robert E Landry officer: SVP Fin, Dep CFO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Neil Stahl officer: SVP, Preclinical Development 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein director DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390